Dyne Therapeutics plans to announce topline results from its DELIVER trial on December 8, 2025, via webcast.
Quiver AI Summary
Dyne Therapeutics, Inc. announced plans to reveal the topline clinical results from the Registrational Expansion Cohort of the Phase 1/2 DELIVER trial for their drug zeleciment rostudirsen (DYNE-251) on December 8, 2025. A webcast will be held at 8:00 a.m. ET, with a press release to be issued prior to the event. The webcast will be accessible on Dyne's website, and a replay will be available for 90 days. Dyne Therapeutics aims to improve the lives of individuals with genetically driven neuromuscular diseases through therapeutics targeting muscle and the central nervous system. They are currently developing programs for conditions like myotonic dystrophy type 1 and Duchenne muscular dystrophy.
Potential Positives
- Dyne Therapeutics is set to announce topline clinical results from their Phase 1/2 DELIVER trial, which could provide significant insights into the efficacy of their treatment, z-rostudirsen (DYNE-251).
- The upcoming webcast and investor conference call demonstrate the company's commitment to transparency and engagement with investors, potentially increasing investor confidence.
- The focus on genetically driven neuromuscular diseases positions Dyne Therapeutics as a leader in a niche but crucial area of healthcare, which can enhance their reputation and market potential.
- The company's ongoing development of various therapeutics targeting major conditions like DM1 and DMD suggests a robust pipeline that may attract further investment and partnerships.
Potential Negatives
- The announcement highlights the upcoming topline clinical results, which may imply that previous results have not met expectations, leading to significant anticipation and pressure on the upcoming data.
- The reliance on a single product (z-rostudirsen) for critical forthcoming results could indicate a lack of diversification in the company’s pipeline, raising concerns about its overall sustainability.
- Investors may perceive the need for a public announcement of clinical results as a sign of uncertainty or volatility regarding the drug’s performance and the company's future prospects.
FAQ
When will Dyne Therapeutics announce topline clinical results?
Dyne Therapeutics plans to announce topline clinical results on December 8, 2025.
What is the DELIVER trial?
The DELIVER trial is a Phase 1/2 clinical study evaluating z-rostudirsen (DYNE-251) for neuromuscular diseases.
Where can I watch the webcast of the results?
The webcast will be available on Dyne Therapeutics' Events & Presentations page on their website.
Will there be a replay of the webcast?
Yes, a replay of the webcast will be available for 90 days following the presentation.
What diseases does Dyne Therapeutics focus on?
Dyne Therapeutics focuses on genetically driven neuromuscular diseases, including DM1 and DMD.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$DYN Insider Trading Activity
$DYN insiders have traded $DYN stock on the open market 9 times in the past 6 months. Of those trades, 1 have been purchases and 8 have been sales.
Here’s a breakdown of recent trading of $DYN stock by insiders over the last 6 months:
- JOHN COX (CEO & President) has made 1 purchase buying 100,000 shares for an estimated $911,000 and 2 sales selling 5,302 shares for an estimated $90,559.
- DOUGLAS KERR (Chief Medical Officer) has made 0 purchases and 3 sales selling 5,305 shares for an estimated $77,075.
- JOHANNA FRIEDL-NADERER (Chief Commercial Officer) has made 0 purchases and 3 sales selling 1,182 shares for an estimated $16,778.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$DYN Hedge Fund Activity
We have seen 147 institutional investors add shares of $DYN stock to their portfolio, and 85 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- RA CAPITAL MANAGEMENT, L.P. removed 9,714,392 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $122,887,058
- JANUS HENDERSON GROUP PLC added 5,307,543 shares (+56.2%) to their portfolio in Q3 2025, for an estimated $67,140,418
- MARSHALL WACE, LLP added 2,565,570 shares (+572.9%) to their portfolio in Q3 2025, for an estimated $32,454,460
- CITADEL ADVISORS LLC added 2,469,561 shares (+261.6%) to their portfolio in Q3 2025, for an estimated $31,239,946
- VANGUARD GROUP INC added 2,109,257 shares (+27.6%) to their portfolio in Q3 2025, for an estimated $26,682,101
- VESTAL POINT CAPITAL, LP added 2,047,500 shares (+281.4%) to their portfolio in Q3 2025, for an estimated $25,900,875
- DEEP TRACK CAPITAL, LP added 2,000,000 shares (+inf%) to their portfolio in Q3 2025, for an estimated $25,300,000
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$DYN Analyst Ratings
Wall Street analysts have issued reports on $DYN in the last several months. We have seen 8 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 11/06/2025
- Stifel issued a "Buy" rating on 07/31/2025
- Chardan Capital issued a "Buy" rating on 07/29/2025
- Raymond James issued a "Outperform" rating on 07/29/2025
- RBC Capital issued a "Outperform" rating on 07/29/2025
- Jones Trading issued a "Buy" rating on 06/26/2025
- Guggenheim issued a "Buy" rating on 06/18/2025
To track analyst ratings and price targets for $DYN, check out Quiver Quantitative's $DYN forecast page.
$DYN Price Targets
Multiple analysts have issued price targets for $DYN recently. We have seen 11 analysts offer price targets for $DYN in the last 6 months, with a median target of $35.0.
Here are some recent targets:
- Tessa Romero from JP Morgan set a target price of $17.0 on 11/14/2025
- Andreas Argyrides from Oppenheimer set a target price of $11.0 on 11/12/2025
- Luca Issi from RBC Capital set a target price of $30.0 on 11/06/2025
- Ananda Ghosh from HC Wainwright & Co. set a target price of $46.0 on 11/06/2025
- Martin Auster from Raymond James set a target price of $35.0 on 08/25/2025
- Paul Matteis from Stifel set a target price of $36.0 on 07/31/2025
- Keay Nakae from Chardan Capital set a target price of $38.0 on 07/29/2025
Full Release
WALTHAM, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it plans to announce topline clinical results from the Registrational Expansion Cohort (REC) of the Phase 1/2 DELIVER trial of zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251) on December 8, 2025, and to host a webcast at 8:00 a.m. ET. The company intends to issue a press release prior to the start of the event.
Investor Conference Call and Webcast
The webcast will be available on the Events & Presentations page of the Investors & Media section of Dyne’s website, and a replay will be accessible for 90 days following the presentation. An accompanying slide presentation will also be available. To view the webcast and replay, please visit
https://investors.dyne-tx.com/news-and-events/events-and-presentations
.
About Dyne Therapeutics
Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities. Learn more at https://www.dyne-tx.com/ and follow us on X , LinkedIn and Facebook .
Contacts:
Investors
Mia Tobias
[email protected]
781-317-0353
Media
Stacy Nartker
[email protected]
781-317-1938
